Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares in the company, valued at $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Tango Therapeutics Trading Down 2.7 %

NASDAQ:TNGX opened at $3.26 on Friday. The firm’s fifty day simple moving average is $3.14 and its 200 day simple moving average is $6.12. Tango Therapeutics, Inc. has a twelve month low of $2.59 and a twelve month high of $12.89.

Institutional Trading of Tango Therapeutics

Several large investors have recently added to or reduced their stakes in TNGX. Catalina Capital Group LLC bought a new stake in Tango Therapeutics in the fourth quarter valued at $82,000. Quest Partners LLC boosted its holdings in shares of Tango Therapeutics by 1,448.4% during the 3rd quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock valued at $84,000 after buying an additional 10,182 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Tango Therapeutics during the 3rd quarter valued at $151,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Tango Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $159,000 after buying an additional 8,055 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at $218,000. Institutional investors own 78.99% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on TNGX. Guggenheim lowered their target price on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research note on Friday, November 8th. B. Riley decreased their price target on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $13.14.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.